96 - A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Virtual

Co-Author(s)

Pedro P. Ylisastigui, MD

Principal Investigator
Alliance For MultiSpecialty Research
Fort Myers, Florida, United States
CL

Chiu-Shong Liu, MD, MPH

China Medical University Hospital
Taichung, Taichung, Taiwan
KT

Kenji Takazawa, PhD MD

Medical Corporation Shinanokai Shinanozaka Clinic
Shinjuku-ku, Tokyo, Japan
MY

Makoto Yono, PhD MD

Nishi-Kumamoto Hospital, Souseikai
Kumamoto, Kumamoto, Japan
JE

John E. Ervin, MD

Principal Investigator
AMR Kansas City
Kansas City, Missouri, United States
CA

Charles Andrews, MD

Diagnostics Research Group
San Antonio, Texas, United States
CF

Charles Fogarty, n/a

Medical Director
Spartanburg Medical Research
Spartanburg, South Carolina, United States
TE

Tamara Eckermann, MD

Hausarztpraxis Heimeranplatz
München, Bayern, Germany
DC

Delphine Collete, PhD

GSK
Rixensart, Brabant Wallon, Belgium
Md

Magali de Heusch, PhD

Expert Scientist
GSK
Wavre, Brabant Wallon, Belgium
ND

Nathalie De Schrevel, PhD

Clinical Readout Team Leader
GSK, Rixensart, Belgium
Rixensart, Brabant Wallon, Belgium
BS

Bruno Salaun, PhD

Senior Scientist
GSK
Rixensart, Brabant Wallon, Belgium
ML

Marc Lievens, MSc

GSK
Wavre, Brabant Wallon, Belgium
CM

Céline Maréchal, PhD

GSK
Wavre, Brabant Wallon, Belgium
PN

Phoebe Nakanwagi, Master’s in Biostatistics

GSK
Wavre, Brabant Wallon, Belgium
VH

Veronica Hulstrøm, PhD MD

GSK, Wavre, Belgium
Wavre, Brabant Wallon, Belgium